FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy